 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Cancer Research UKs Commercial Partnerships has permitted Lineage to conduct an early exercise of its option to acquire data from Cancer Research UKs ongoing Phase 1 clinical trial of VAC2 in non-small cell lung cancer NCT03371485, and develop an allogeneic dendritic cell therapy platform VAC. Lineage will assume responsibility for further development of the VAC2 product candidate as well as future development opportunities derived from the VAC platform, while Cancer Research UK concludes the ongoing trial. This decision was based on an early review of the data collected by Cancer Research UK in the VAC2 trial under a clinical trial and option agreement. In addition, Cancer Research UK will provide input on the potential use of VAC in the infectious disease space to develop a vaccine against SARS-CoV-2, the virus which causes COVID-19. Cancer Research UK is the worlds largest cancer charity dedicated to saving lives through research. 